ESR1 and breast carcinoma: Li et al. [190] demonstrated in a recent work that EGCG in combination with class I HDAC inhibitor, trichostatin A (TSA), could synergistically reactivate ERα expression in ERα negative MDA-MB-231 breast cancer cells by modulating histone methylation and acetylation pattern at the gene promoter.